FDA Brief

Warning letters Drugs

FDA warning letter to

Aqualex Co., Ltd.

High riskIssued Jun 12, 2024Posted Jun 18, 2024Center for Drug Evaluation and Research | CDER

Aqualex, a Korean contract manufacturer, was cited for manufacturing failures and an unapproved OTC sunscreen with misleading labeling.

What happened

FDA inspected Aqualex’s drug manufacturing facility from October 16 to 20, 2023, and found CGMP (manufacturing quality rules) violations, including no process validation or equipment qualification, a water system with stagnant dead-legs, weak quality-unit record controls and data integrity, inadequate microbial release testing, and insufficient stability data. The firm’s November 9, 2023 response to the Form FDA 483 (inspection observations) was inadequate. FDA also reviewed the label and website for “DBH Beverly Hills, EGF FGF DNA, UV Shield” and found it was an unapproved new drug and misbranded, including an “OCTINOXATE FREE” website claim that conflicted with the label listing octinoxate.

What FDA found

  1. The firm lacked adequate written production and process controls and did not show that its manufacturing processes and equipment were validated or qualified.

    21 CFR 211.100(a)
  2. The firm used an inadequately designed water system with stagnant water points, including a dead-leg at a point of use.

    21 CFR 211.63
  3. The quality unit did not adequately control CGMP records or ensure data integrity, including original records in a shredding container and laboratory data first recorded on temporary records.

    21 CFR 211.22
  4. The firm released batches without adequate laboratory testing, including required microbial testing and growth promotion testing of media.

    21 CFR 211.165(b)
  5. The firm lacked adequate stability data to support its labeled 3-year expiry and proposed using a bulk container not representative of the marketed container closure.

    21 CFR 211.166(a)
  6. The sunscreen was an unapproved new drug because DNA, EGF, and FGF were not permitted sunscreen active ingredients under the monograph, and it was misbranded because website and label claims conflicted.

    FD&C Act sections 505(a), 301(d), 502(a), 502(b), 502(e), and 502(ee)

What FDA wants

FDA asks Aqualex to provide detailed corrective action plans and evidence for validation, water system remediation, quality-unit and document controls, laboratory testing including retain-sample testing, and stability, and recommends a qualified CGMP consultant and six-system audit before seeking resolution. No response deadline is stated in the letter.

Who should pay attention

  • brands that buy OTC sunscreen or other drugs from this contract manufacturer
  • U.S. distributors and retailers selling DBH Beverly Hills UV Shield
  • quality teams relying on supplier certificates for microbial media or water testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk